Skip to main content

Research Repository

Advanced Search

Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline focused update

Wolff, Antonio C.; Hammond, M. Elizabeth Hale; Allison, Kimberly H.; Harvey, Brittany E.; Mangu, Pamela B.; Bartlett, John M.S.; Bilous, Michael; Ellis, Ian O.; Fitzgibbons, Patrick; Hanna, Wedad; Jenkins, Robert B.; Press, Michael F.; Spears, Patricia A.; Vance, Gail H.; Viale, Giuseppe; McShane, Lisa M.; Dowsett, Mitchell

Authors

Antonio C. Wolff

M. Elizabeth Hale Hammond

Kimberly H. Allison

Brittany E. Harvey

Pamela B. Mangu

John M.S. Bartlett

Michael Bilous

Patrick Fitzgibbons

Wedad Hanna

Robert B. Jenkins

Michael F. Press

Patricia A. Spears

Gail H. Vance

Giuseppe Viale

Lisa M. McShane

Mitchell Dowsett



Abstract

© 2018 College of American Pathologists Published by the College of American Pathologists Allen Press, Inc. Purpose. - To update key recommendations of the American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) human epidermal growth factor receptor 2 (HER2) testing in breast cancer guideline. Methods. - Based on the signals approach, an Expert Panel reviewed published literature and research survey results on the observed frequency of less common in situ hybridization (ISH) patterns to update the recommendations. Recommendations. - Two recommendations addressed via correspondence in 2015 are included. First, immunohistochemistry (IHC) 2+ is defined as invasive breast cancer with weak to moderate complete membrane staining observed in >10% of tumor cells. Second, if the initial HER2 test result in a core needle biopsy specimen of a primary breast cancer is negative, a new HER2 test may (not ''must'') be ordered on the excision specimen based on specific clinical criteria. The HER2 testing algorithm for breast cancer is updated to address the recommended workup for less common clinical scenarios (approximately 5% of cases) observed when using a dual-probe ISH assay. These scenarios are described as ISH group 2 (HER2/ chromosome enumeration probe 17 [CEP17] ratio ≥2.0; average HER2 copy number

Citation

Wolff, A. C., Hammond, M. E. H., Allison, K. H., Harvey, B. E., Mangu, P. B., Bartlett, J. M., …Dowsett, M. (2018). Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline focused update. Archives of Pathology and Laboratory Medicine, 142(11), 1364-1382. https://doi.org/10.5858/arpa.2018-0902-sa

Journal Article Type Article
Acceptance Date May 30, 2018
Online Publication Date Nov 1, 2018
Publication Date Nov 1, 2018
Deposit Date Aug 8, 2019
Publicly Available Date Aug 8, 2019
Journal Archives of Pathology & Laboratory Medicine
Print ISSN 0003-9985
Electronic ISSN 1543-2165
Publisher College of American Pathologists
Peer Reviewed Peer Reviewed
Volume 142
Issue 11
Pages 1364-1382
DOI https://doi.org/10.5858/arpa.2018-0902-sa
Public URL https://nottingham-repository.worktribe.com/output/2406986
Publisher URL https://www.archivesofpathology.org/doi/10.5858/arpa.2018-0902-SA

Files

Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer (1.5 Mb)
PDF




You might also like



Downloadable Citations